Compare GraniteShares 2x Long COIN Daily ETF (CONL) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long COIN Daily ETF vs Sanofi SA — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $4.12, while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA pays a 5.55% dividend while GraniteShares 2x Long COIN Daily ETF pays none, and Sanofi SA is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals.
| CONL | SNY | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $48.70 | $52.34 |
52-Week Low | $3.93 | $41.33 |
Market Cap | — | $104.30B |
Enterprise Value | — | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONL, the GraniteShares 2x Long COIN Daily ETF, trades at $4.11, up 0.49% on the day but reflecting a bearish technical signal with moving averages indicating strong selling pressure. The ETF has experienced significant volatility and value erosion, with news highlighting a 67% year-to-date loss as of June 2026 due to the daily-reset leverage structure amplifying Coinbase's price swings. Key financial ratios are not applicable as this is a leveraged ETF tracking another security.
Outlook remains highly speculative and risky due to the ETF's daily leverage, which can lead to rapid losses in volatile markets. Investment opportunity is limited to short-term traders betting on Coinbase rallies, but risks include volatility decay, tracking error, and dependence on Coinbase performance. Long-term holding is discouraged by the structure's inherent erosion.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GraniteShares 2x Long COIN Daily ETF
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
